NasdaqHealth CarePharmaceutical PreparationsPRINCETON, NJ

Grace Therapeutics, Inc. GRCE

Ask your AI

Estimated market cap $38.08M21.04M shares, shares as of Nov 11, 2026CIK 1444192

Insider trades, 12 mo

15 buys · 0 sells

$637.7K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

10.3% of shares · 2 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Grace Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Grace Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

15 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Recent insider trades

Opaleye Management Inc. 10% owner	Nov 5 Form 4 ↗	Buy	+$5,478 3,087 sh @ $1.77	-1.2%
Opaleye Management Inc. 10% owner	Nov 4 Form 4 ↗	Buy	+$9,060 5,027 sh @ $1.80	+1.6%
Opaleye Management Inc. 10% owner	Nov 3 Form 4 ↗	Buy	+$18.5K 10,328 sh @ $1.79	-1.6%
Opaleye Management Inc. 10% owner	Oct 26 Form 4 ↗	Buy	+$117.4K 66,411 sh @ $1.77	+1.4%
Opaleye Management Inc. 10% owner	Oct 22 Form 4 ↗	Buy	+$41.2K 21,390 sh @ $1.93	-4.2%

All GRCE insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

2.16M shares

23 funds report GRCE. Values checked against market prices.

Funds own 24% of shares (Q2 2026)

33 funds hold the stock.

Q3 2026: 10% · 5,560 of ~8,900 funds reported so far

Q2 202528%
Q3 202524%
Q4 202528%
Q1 202628%
Q2 202624%
Q3 2026 (so far)10%

Q3 2026. 10 new, 2 added to, 5 trimmed, 19 exited since Q2 2026.

Top 13F holders
#
1	Cerity Partners LLC 13F ↗	849,055	$1.8M	unchanged
2	Nantahala Capital Management, LLC 13F ↗	476,190	$1.0M	New
3	Vanguard Capital Management LLC 13F ↗	400,350	$860.8K	-2.8%
4	Renaissance Technologies LLC 13F ↗	186,134	$400.2K	New
5	Jane Street Group, LLC 13F ↗	62,725	$134.9K	-29.9%
6	BlackRock, Inc. 13F ↗	35,915	$77.2K	-4.3%
7	Citigroup Inc 13F ↗	35,481	$76.3K	New
8	Kestra Private Wealth Services, LLC 13F ↗	23,000	$49.5K	unchanged
9	Morgan Stanley 13F ↗	22,763	$48.9K	+140.9%
10	Johnson Dunn Capital Advisors Inc 13F ↗	19,500	$41.9K	New

Download CSV Every fund that holds GRCE, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Recent congressional trades
Member	Transaction	Amount	Traded → disclosed	Since trade
Mark E. Green R House · TN	Purchase Joint account	$1,001 - $15,000	Mar 16 → Mar 28 ↗ 12d	—

All 1 trade →Free on every plan.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Grace Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Grace Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2024	1	—	959,571	$2.9M
Q4 2024	15	+14	2.09M	$7.8M
Q1 2025	17	+2	4.02M	$9.2M
Q2 2025	20	+3	3.82M	$11.3M
Q3 2025	20	0	3.71M	$11.0M
Q4 2025	22	+2	4.33M	$15.0M
Q1 2026	34	+12	4.26M	$19.7M
Q2 2026	33	-1	3.95M	$9.0M
Q3 2026	23	-10	2.16M	$4.6M

Each point is a quarter-end, from Q3 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (00439U104). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes9 in 12 mo 8-K events2 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Grace Therapeutics, Inc.
Address: 103 CARNEGIE CENTER, SUITE 300, PRINCETON, NJ 08540
Phone: 609-322-1602
Fiscal year ends: Mar 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: GRCE (Nasdaq)
Former names: Acasti Pharma Inc. (until 2024)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.81$0.00 (0.00%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.78 · High $2.01Nov 13, 2026

Aug 13, 2026Low $1.78 · High $2.29Nov 13, 2026

Nov 13, 2025Low $1.78 · High $5.13Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.